Item 1.01 Entry into a Material Definitive Agreement.
On
May 15, 2023, Modular Medical, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”)
with Newbridge Securities Corporation (“Newbridge” or the “Underwriter”), with respect to the issuance and sale
in a firm commitment underwritten offering (the “Offering”) by the Company of units of its securities for aggregate gross
proceeds of $9,400,000. Each unit consists of two shares of common stock of the Company, par value $0.001 per share (the “Common
Stock”), and one warrant (the “Warrants” and together with the Common Stock, the “Securities”) to purchase
one share of Common Stock, at a public offering price of $2.13 per unit. The Warrants will be immediately separable and exercisable, shall have
a per share exercise price of $1.22, and will expire five years from the date of issuance.
Pursuant
to the Underwriting Agreement, the Company granted the Underwriter a 30-day option to purchase up to an additional 1,322,534 shares
of Common Stock and an additional 661,267 Warrants to cover over-allotments, if any. Newbridge is acting as the sole book-running manager
of the Offering. The Underwriter will be entitled to a cash fee of 7.0% of the aggregate gross proceeds of the Offering and the reimbursement
of certain out-of-pocket expenses of up to $125,000. In connection with the Offering, the Company agreed to issue to Newbridge warrants
to purchase that number of shares of Common Stock equal to an aggregate of 7% of the total shares sold in the Offering.
The
Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing,
indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended,
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement and related
“lock-up” agreements, the Company, each director and executive officer of the Company, and certain stockholders have agreed
with the Underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our Common Stock or
securities convertible into Common Stock for a period of 90 days after the date on which a final prospectus relating to the Offering
is filed with the Securities and Exchange Commission (the “SEC”).
The
Offering is expected to close on May 18, 2023, subject to customary closing conditions.
The
net proceeds to the Company from the Offering, after deducting the Underwriter’s fees and expenses and the Company’s estimated
offering expenses, are expected to be approximately $8.3 million. The Company intends to use the net proceeds from the Offering for general
corporate purposes, including working capital, to fund its operations through the approval of its product by the FDA, to develop its
initial sales and marketing infrastructure, to fund additional research and development activities, to develop initial manufacturing
and production capabilities and make related capital expenditures.
The
Offering was registered with the Commission pursuant to a Registration Statement on Form S-1, as amended (File No. 333-271413), initially
filed by the Company on April 24, 2023, which became effective on May 15, 2023.
The
Warrants will be issued pursuant to a warrant agency agreement to be entered into by and between the Company and Colonial Stock Transfer
Company, Inc., as warrant agent.
The
foregoing descriptions of the terms and conditions of the Underwriting Agreement do not purport to be complete and are qualified in their
entirety by the full text of the Underwriting Agreement, a copy of which is hereto as Exhibit 1.1 and which is incorporated herein by
reference.
The
legal opinion and consent of Lucosky Brookman LLP relating to the securities is filed as Exhibit 5.1 to this Current Report on Form 8-K
and is incorporated herein by reference.